Arming NK cells with enhanced antitumor activity
CARs and beyond

Pranav Oberoi and Winfried S Wels*

Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus; Frankfurt am Main, Germany

Keywords: chimeric antigen receptor, granzyme B, NK cells

Natural killer (NK) cells hold great promise for adoptive cancer immunotherapy. The antitumor activity of NK cells can be enhanced by the transgene driven expression of chimeric antigen receptors that facilitate the selective recognition and killing of malignant cells. Recent data from our laboratory suggest that NK cells may similarly be "armed" against neoplastic cells by the expression of cancer-specific granzyme B-containing fusion proteins that are released as soluble factors upon NK-cell activation.

Natural killer (NK) cells play an important role in the defense against viral infection and the elimination of neoplastic cells. The natural cytotoxic function of NK cells can be rapidly activated upon appropriate stimulation, and is regulated by a complex balance of signals originating from germline-encoded activating and inhibitory receptors. Following the recognition of target cells and activation, lytic granules within NK cells are polarized toward the immunological synapse, where they fuse with the plasma membrane and release their contents into the so-called synaptic cleft, i.e., the small space between effector and target cells (Fig. 1A).

The importance of NK cells for cancer immunosurveillance has been extensively documented in mouse models. A correlation between a reduced activity of circulating NK cells and an increased risk of cancer has been demonstrated also in humans. Of note, in contrast to B and T lymphocytes, NK cells are intrinsically programmed to detect modifications in cellular metabolism or gene expression that are concurrent with oncogenesis. Hence, different strategies are being developed to employ NK cells for anticancer immunotherapy. These include the activation of autologous NK cells, the adoptive transfer of allogeneic NK cells, and the pharmacological or genetic modulation of NK-cell functions.

Like T cells, NK cells can be genetically modified to express chimeric antigen receptors (CARs), allowing them to selectively recognize tumor-associated cell surface antigens and hence increasing their specificity and antineoplastic activity. Typically, a CAR consists of an extracellular single-chain antibody fragment (scFv, for the recognition for tumor-associated antigens) that is linked via a transmembrane domain to an intracellular signaling moiety such as a CD3ζ chain or a CD3ζ chain coupled to a co-stimulatory protein domain. The engagement of CARs expressed by NK cells triggers the antigen-specific lysis of target cells, hence bypassing the need for the activation of endogenous cytotoxicity receptors (Fig. 1B). This may be of particular advantage in the case of solid neoplasms, as malignant cells from this type of cancer display a varying degree of resistance to the lytic activity of unmodified NK cells, but can be readily killed in an antigen-dependent manner by NK cells expressing suitable CARs.

As a novel approach to provide NK cells with target-specific cytotoxic functions and augment their antitumor activity, we have recently tested the ectopic expression of a chimeric granzyme B (GrB)-containing fusion protein by NK cells. GrB is a pro-apoptotic serine protease that plays a crucial role in NK-cell mediated cytotoxicity. GrB is synthesized as an inactive precursor protein (pre-pro-GrB) bearing an N-terminal signal peptide that directs the protein into secretory granules and an activation dipeptide. The removal of this activation peptide by the cysteine protease cathepsin C generates the enzymatically active form of GrB, which is stored together with other granzymes and perforin in the dense core of lytic granules. Following the recognition of target cells and activation, NK cells release mature GrB specifically in the immunological synapse, from where it enters target cells in cooperation with perforin, rapidly inducing their death.

For expression in NK cells, we generated a tumor-specific GrB-based chimera by fusing the epidermal growth factor receptor (EGFR)-specific ligand transforming growth factor α (TGFα) to the C-terminus of human pre-pro-GrB. Unlike bacterial or yeast expression systems previously employed for the generation of recombinant GrB fusion proteins, NK cells possess the entire molecular machinery that is required for the processing, packaging, and triggered release of endogenous GrB, which may also be employed by an ectopically expressed, targeted GrB derivative. Following lentiviral vector-based gene transfer, NK cells
readily expressed the GrB-TGFα fusion protein in amounts comparable to endogenous wild-type GrB. Moreover, the activation of genetically modified NK cells by target cells led to the release of correctly processed and enzymatically active GrB-TGFα together with endogenous granzymes and perforin. This facilitated the cooperation between tumor-specific GrB-TGFα and natural cytotoxic effectors of NK cells, resulting in enhanced antitumor activity against NK cell-sensitive targets (Fig. 1C). The GrB-TGFα chimera enriched from the supernatant of artificially activated NK cells displayed EGFR-specific binding as well as the ability to kill EGFR-expressing neoplastic cells in the presence of an endosomolytic activity. Nevertheless, EGFR-expressing malignant cells originating from solid tumors failed to activate natural cytotoxicity receptors, thereby avoiding lysis by parental as well as by GrB-TGFα-expressing NK cells. To overcome this issue, we are currently investigating the co-expression of tumor-targeted GrB variants with CARs that ensure NK-cell activation even by otherwise resistant cancer cells. In this scenario, CARs and targeted GrB may be directed to the same or distinct tumor-associated cell surface antigens.

References
1. Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 2008; 8:713-25; PMID:19172692; http://dx.doi.org/10.1038/nri2381
2. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurev-immunol-031210-101324
3. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356:1795-9; PMID:11117911; http://dx.doi.org/10.1016/S0140-6736(00)03231-1

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
4. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12:239-52; PMID:22437937; http://dx.doi.org/10.1038/nri3174
5. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 2008; 9:486-94; PMID:18425105; http://dx.doi.org/10.1038/ni1580
6. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002; 100:1265-73; PMID:12149207
7. Sahm C, Schönfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 2012; 61:1451-61; PMID:22310931; http://dx.doi.org/10.1007/s00262-012-1212-x
8. Stojanovic A, Cerwenka A. Natural killer cells and solid tumors. J Innate Immun 2011; 3:355-64; PMID:21502747; http://dx.doi.org/10.1159/000325465
9. Oberoi P, Jabulowsky RA, Bähr-Mahmud H, Wels WS. EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells. PLoS One 2013; 8:e61267; PMID:23573299; http://dx.doi.org/10.1371/journal.pone.0061267
10. Oberoi P, Jabulowsky RA, Wels WS. Selective induction of cancer cell death by targeted granzyme B. Antibodies 2013; 2:130-51; http://dx.doi.org/10.3390/antib2010130